본문으로 건너뛰기
ProhibitedBinding ruleSAOriginal is English공식 출처 가져오기 확인됨

Methylphenidate (INN) and its salts

Listed by the Saudi Food and Drug Authority as prohibited in cosmetic products.

규제 판단 및 전체 조건

상태
Prohibited
법적 역할
Binding rule
규제 요약
Listed by the Saudi Food and Drug Authority as prohibited in cosmetic products.
조건 및 제한 사항
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. 인용된 출처를 열고 아래의 시장 전체 요건을 적용하세요.

물질 정체

공식 출처상의 명칭
Methylphenidate (INN) and its salts
CAS
113-45-1
EC
Not supplied in this source row
정체 매핑
standalone:official_sfda_record

이 정체의 시장 간 요약

현재 이 사이트에 있는 정확히 연결된 기록입니다. 시장이 없는 것은 가져온 정확한 일치 항목이 없다는 뜻이며, 해당 물질의 사용이 허용된다는 뜻이 아닙니다.

시장 데이터세트 10개

South Korea

Prohibited

연결된 기록 1건 · 특정 조건이 있는 기록 1건

보조 기록 열기
CAS 113-45-1의 PubChem 2D 화학 구조
CAS 113-45-1PubChem CID 4158

CAS 113-45-1의 검증된 화학 정보

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

IUPAC 명칭
methyl 2-phenyl-2-piperidin-2-ylacetate
분자식
C14H19NO2
분자량
233.31 g/mol
정확한 질량
233.141578849 Da
단일 동위원소 질량
233.141578849 Da
XLogP3
0.2
위상 극성 표면적
38.3 Ų
분자 복잡도
249.0
형식 전하
0
수소 결합 공여체
1
수소 결합 수용체
3
회전 가능 결합
4
중원자
17
공유결합 단위
1

PubChem에 보고된 명칭 및 동의어

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
보고된 명칭 16개 더 보기
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
외부 데이터베이스 식별자
고급 구조 통계
정의된 원자 입체중심
0
정의되지 않은 원자 입체중심
2
정의된 결합 입체중심
0
정의되지 않은 결합 입체중심
0
3D 파마코포어 특성
5
3D 고리
2
3D 소수성 부위
0
3D 수용체 특성
1
3D 공여체 특성
1
3D 음이온 중심
0
3D 양이온 중심
1
3D 형태이성질체
10
유효 3D 회전자
5.2
기계 판독 가능한 구조 식별자
SMILES
COC(=O)C(C1CCCCN1)C2=CC=CC=C2
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
InChIKey
DUGOZIWVEXMGBE-UHFFFAOYSA-N

추가 과학 데이터베이스의 근거

NIH PubChem PUG-View
식별자 정확히 일치4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. 출처: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning 출처: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] 출처: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 출처: European Chemicals Agency (ECHA)
  • Signal: Danger 출처: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 출처: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) 출처: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. 출처: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre 출처: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. 출처: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. 출처: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 출처: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. 출처: Toxin and Toxin Target Database (T3DB)

매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기

과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.

추가 출처 적용 범위 및 일치 상태
출처결과확인됨
NIH PubChem PUG-View정확히 일치2026-08-31

기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.

체크섬이 유효한 CAS 일치를 통해 2026-09-02에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.

공식 출처 및 출처 정보

등록된 출처
Saudi SFDA prohibited and restricted ingredient lists
출처 참조
SFDA prohibited list, page 18, row 7
출처 기록 ID
prohibited-17-7
출처 버전
live-snapshot-2026-08-30
출처 언어
English
번역 상태
Original is English
스냅샷 확인
2026-08-30 05:18 UTC
검증 방법
complete SFDA paginated HTML snapshot; strict page/row counts
SHA-256
ceb6cc636e6b1f4b3013f88ce0297217b49d6194342c6ece5c03b1e04256d71a

등록된 데이터세트 주석

데이터세트 적용 범위
Prohibited and restricted substances with CAS, EC and conditions
권위 관련 주석
Official SFDA dated lists; version and hash each release

이 기록이 시장 데이터세트에서 차지하는 위치

2090
현재 Saudi Arabia 기록
1726
Prohibited(으)로 표시된 기록
2090
이 출처 버전의 기록
1991
CAS 정체가 있는 시장 기록

상태 분포

현재 기록 2090건 중 0건에 조건 텍스트가 있습니다. 조건 필드가 비어 있는 경우 위의 기록 유형에 따라 해석되며, 제한 없는 사용에 대한 주장으로 전환되지 않습니다.

Saudi Arabia 시장 맥락

Complete official list index

적용 범위 버전: SFDA live prohibited/restricted lists, snapshot 30 August 2026

Every page and entry in the public SFDA prohibited and restricted ingredient indexes; restricted detail pages remain the source for conditions.

확인 체크리스트

  1. Search names and CAS across both SFDA lists.
  2. Open the cited restricted-entry detail and apply every condition.
  3. Check current SFDA/GSO technical regulations and updates.
  4. Complete eCosma notification, label and responsible-party requirements.

공식 시장 출처

확인 절차 및 기록 완전성

이 결과를 규제 준수 판단에 사용하기 전에

  1. “Methylphenidate (INN) and its salts”와(과) 모든 CAS/EC 식별자가 공급업체 규격서의 물질을 가리키는지 확인하세요.
  2. Search names and CAS across both SFDA lists.
  3. Open the cited restricted-entry detail and apply every condition.
  4. Check current SFDA/GSO technical regulations and updates.
  5. Complete eCosma notification, label and responsible-party requirements.
  6. 출처 버전을 기록하고, 제조, 신고 또는 시장 출시 전에 규제 기관을 다시 확인하세요.

이 기록에서 제공되는 필드

  • 공식 물질 명칭제공됨
  • CAS제공됨
  • EC제공되지 않음
  • 별도의 조건 텍스트출처 행에 없음
  • 시행일제공되지 않음
  • 스냅샷 해시 및 방법제공됨

이 페이지가 답하는 질문

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.

이 기록은 SFDA prohibited list, page 18, row 7, 출처 버전 live-snapshot-2026-08-30을(를) 인용합니다. 공식 출처를 여세요.

아니요. CAS는 정체를 확인하는 데 도움이 되지만, 관할권마다 같은 물질을 다르게 분류할 수 있으며 제품 범위, 한도, 경고 문구 및 경과 기간 날짜를 다르게 적용할 수 있습니다.

안정적인 인용

Methylphenidate (INN) and its salts. SFDA prohibited list, page 18, row 7. Saudi Arabia. Source version live-snapshot-2026-08-30. CosIng Checker regulatory record: https://cosingchecker.com/ko/regulations/sa/records/9776/

법적 권위로서 규제 기관을 인용하세요. 이 페이지는 구조화된 근거 색인이자 확인 보조 도구이며, 공식 본문이나 전문적인 법률 평가를 대체하지 않습니다.

Saudi Arabia의 해석 및 한계

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

법적 역할 해석 방법

The cited row forms part of a binding rule or legally incorporated list for this market.

이 페이지의 근거

  • 기록된 결과: Prohibited
  • 법적 역할: Binding rule
  • 출처 버전: live-snapshot-2026-08-30

증명하지 않는 것

No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.

추가 공신력 있는 물질 조사

이 출처들 중 어느 것도 위의 시장 판단을 번복하지 않습니다.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

출처에서 이 정체 조사

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

출처에서 이 정체 조사

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

출처에서 이 정체 조사

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

출처에서 이 정체 조사

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

출처에서 이 정체 조사

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

출처에서 이 정체 조사

US EPA CompTox CTX APIs

가져오기에 API 키 필요

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

출처에서 이 정체 조사